Streetbeat News

Analyst Ratings

DIS

A significant amount of unusual options activity has been observed for Walt Disney (NYSE:DIS), with a majority of investors taking a bearish stance. Whales have been targeting a price range from $50.0 to $160.0 for Walt Disney over the last 3 months. The price of DIS is currently up 0.6% at $89.23. Truist Securities, Morgan Stanley, and Loop Capital have maintained their Buy and Overweight ratings on Walt Disney, with price targets of $105, $110, and $120 respectively.

Portfolio Pulse from Benzinga Insights

June 27, 2023 | 8:01 pm

MS

A significant amount of unusual options activity has been observed for Morgan Stanley (NYSE:MS), indicating that a large investor or institution has taken a bullish stance on the company. The overall sentiment of these big-money traders is split between 60% bullish and 40% bearish. The whales have been targeting a price range from $65.0 to $95.0 for Morgan Stanley over the last 3 months. Citigroup has downgraded its action to Neutral with a price target of $95.

Portfolio Pulse from Benzinga Insights

June 27, 2023 | 8:01 pm

ROK

Over the last quarter, Rockwell Automation (NYSE:ROK) has received a mix of analyst ratings, with 1 bullish, 1 somewhat bullish, 5 indifferent, and 2 somewhat bearish. The company's average 12-month price target has increased by 6.55% from the previous average, now standing at $283.56. Analysts' ratings are determined through various methods, including attending company meetings, researching financial statements, and communicating with insiders.

Portfolio Pulse from Benzinga Insights

June 27, 2023 | 8:00 pm

GWRE

Analysts have provided various ratings for Guidewire Software (NYSE:GWRE) within the last quarter, with 2 bullish, 3 somewhat bullish, 1 indifferent, and 1 somewhat bearish. The average 12-month price target for Guidewire Software is $85.57, which has increased by 12.0% over the past month.

Portfolio Pulse from Benzinga Insights

June 27, 2023 | 8:00 pm

GILT

Needham analyst Ryan Koontz initiates coverage on Gilat Satellite Networks Ltd (NASDAQ:GILT) with a Buy rating and a price target of $7. He anticipates rising profitability and FCF in the company's Peru business and believes GILT can take advantage of rapidly expanding opportunities in the multi-orbit satellite sector. The company's Peru terrestrial network is nearing completion, and he expects a near-term upturn in its profits and FCF. GILT shares traded higher by 6.27% at $6.10 on the last check Tuesday.

Portfolio Pulse from Anusuya Lahiri

June 27, 2023 | 8:00 pm

META

Citigroup analyst Ronald Josey has maintained a 'Buy' rating for Meta Platforms Inc (NASDAQ:META) and raised the price target from $315 to $360. This is due to Reels ad loads reaching 17% QTD, and the broader online advertising market showing stability. Josey projects a 14% Y/Y advertising revenue growth for Meta in 2024.

Portfolio Pulse from Anusuya Lahiri

June 27, 2023 | 7:56 pm

MU

Raymond James analyst Srini Pajjuri maintains an Outperform rating on Micron Technology, Inc (NASDAQ:MU), despite expecting a potential revenue decline due to China's CAC decision. However, he believes the impact will be short-lived and anticipates a cyclical recovery starting in the second half of FY23. He also expects customer inventories to normalize by the calendar 4Q and predicts better supply discipline in the industry due to the current downturn.

Portfolio Pulse from Anusuya Lahiri

June 27, 2023 | 7:54 pm

COIN

Coinbase Global shares are trading higher, possibly due to a recent rise in Bitcoin and positive comments from Baupost Group CEO Seth Klarman.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 7:48 pm

META

Citigroup has raised its price target on Meta's stock from $315 to $360, leading to a rise in Meta's share prices.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 7:27 pm

NKTX

Nkarta Inc's Phase 1 study of NKX101 for treating acute myeloid leukemia (AML) has been deemed a setback by Needham, leading to a revised development timeline and a lowered price target from $26 to $19. The company plans to enroll more patients in the trial and provide an update in 1H 2024. NKTX shares are down 35.50% at $2.92.

Portfolio Pulse from Vandana Singh

June 27, 2023 | 7:13 pm